FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a method of treating cancer. Method of treating cancer involves administering to a subject a composition comprising apilimod or a pharmaceutically acceptable salt thereof, in an amount effective for inhibiting cellular PIKfyve activity in the individual's cancer cells, and administering an additional agent selected from signaling point control point inhibitors, including a trigger for programmed death of 1 (PD-1) and/or its ligands (PD-L1/2).
EFFECT: invention provides treating cancer in a subject in need thereof by synergetic action occurring when using apilimod in combination with PD-1 or PD-L1/2 inhibitors.
17 cl, 9 dwg, 10 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APILIMOD FOR USE IN TREATING RENAL CANCER | 2015 |
|
RU2727802C2 |
| METHODS FOR IMMUNOTHERAPY WITH CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH 4-1BB AGONIST | 2019 |
|
RU2788524C2 |
| TREATING MALIGNANT TUMORS USING PIZ-KINASE ISOFORM MODULATORS | 2014 |
|
RU2705204C2 |
| USE OF MITOXANTHRON LIPOSOME FOR THE TREATMENT OF NON-HODGKIN'S LYMPHOMA | 2019 |
|
RU2804477C2 |
| TREATING MALIGNANT TUMOURS USING MODULATORS OF PI3-KINASE ISOFORMS | 2013 |
|
RU2702908C2 |
| APILIMOD COMPOSITION AND METHODS OF USING IT IN TREATING MELANOMA | 2015 |
|
RU2731908C2 |
| METHODS FOR TREATMENT OF LYMPHOMA | 2019 |
|
RU2784243C2 |
| DEVICES AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | 2018 |
|
RU2795984C2 |
| TREATING A MALIGNANT TUMOR USING A CHIMERIC ANTIGEN CD19 RECEPTOR | 2015 |
|
RU2718542C2 |
| NOVEL APPROACH TO CANCER TREATMENT USING IMMUNOMODULATION | 2016 |
|
RU2817047C2 |
